<DOC>
	<DOCNO>NCT00879476</DOCNO>
	<brief_summary>The study conduct open label , balance , randomize , two-treatment , two-period , two-sequence , single-dose , crossover bioavailability study compare Ramipril capsule 10 mg OHM Laboratories Inc. , USA ALTACEÂ® ( ramipril ) capsule 10 mg manufacture King Pharmaceuticals Inc. , Bristol , TN 37620 , USA healthy , adult , male , human subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Ramipril 10 mg Capsules Under Fasting Conditions</brief_title>
	<detailed_description>Following overnight fast least 10 hour , single oral dose ramipril 10 mg capsule administer period study , along 240 mL drink water ambient temperature , low light condition supervision train study personnel . A total sixty-eight ( 68 ) subject enrol study , administer single oral dose test reference formulation ramipril 10 mg capsule accord randomization schedule . Two subject ( subject number 01 06 ) withdrawn study period I subject number 02 report period II . Sixty-five ( 65 ) subject complete period study .</detailed_description>
	<mesh_term>Ramipril</mesh_term>
	<criteria>1 . Were age range 1845 year . 2 . Were neither overweight underweight correspond height per Life Insurance Corporation India height/weight chart nonmedical case . 3 . Had voluntarily give write informed consent participate study . 4 . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . 1 . Hypersensitivity allergy ramipril relate group drug . 2 . Subject sit systolic blood pressure le 90 mmHg &gt; 140 mmHg diastolic blood pressure le 60 mmHg &gt; 90 mm Hg screen 3 . History hypertension , hypotension , angina , myocardial infarction angioedema . 4 . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . 5 . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes , glaucoma angioedema due cause . 6 . History psychiatric illness might impair ability provide write informed consent . 7 . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . 8 . Presence value significantly different normal reference range and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . 9 . Positive urinary screen test drug abuse ( opiates cannabinoids ) 10 . Presence value significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . 11 . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . 12 . Clinically abnormal ECG Chest Xray . 13 . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . 14 . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . 15 . Use enzyme modifying drug within 30 day prior Day 1 study . 16 . Participation clinical trial within 12 week precede Day 1 study . 17 . Subjects , completion study , would donate and/or lose 350 mL blood past month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Bioequivalence ramipril fast condition</keyword>
</DOC>